Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ Annual report pursuant to section 13 or 15(d) of the Securities Exchange Act of 1934. For the fiscal year ended April 29, 2022. ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File No. 1-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State or other ...

Medtronic plc (NYSE:MDT) Conference Call Summary Company Overview - **Company**: Medtronic plc - **Event**: Goldman Sachs Global Healthcare Conference Call - **Date**: June 14, 2022 - **Participants**: Geoff Martha (Chairman & CEO), Amit Hazan (Goldman Sachs Medical Technology Analyst) Key Points Industry Context - The healthcare industry, particularly medical technology, has faced significant challenges due to COVID-19 and supply chain disruptions [4][5][6] - Medtronic has played a critical role in responding to the pandemic, particularly with ventilators [4] Supply Chain Challenges - Medtronic experienced acute supply chain issues, particularly with semi chips and resins affecting their Energy business and packaging [7][8] - A supplier explosion caused significant disruptions in the Surgical Innovations business [8] - Supply chain issues are expected to improve, particularly in the second half of the fiscal year [9] - The company is implementing structural changes to enhance supply chain resiliency, moving from a fragmented approach to a centralized model [11][12][14] Financial Guidance and Revenue Expectations - Medtronic is guiding for 4% to 5% revenue growth for the fiscal year, despite challenges in the previous quarters [22][24] - The company anticipates easier comparisons in the second half of the fiscal year due to lower bases from the previous year [25] - Key product launches are expected to drive growth, including new TAVR and EV ICD products [26] Research and Development (R&D) - Medtronic aims to increase R&D spending to outpace sales growth, focusing on higher-growth opportunities [28] - The company is committed to improving R&D productivity and has streamlined operations to allow for increased investment [29] Operating Margins - Medtronic is targeting a return to pre-COVID operating margins of around 28% [30][32] - The company is focused on achieving 5% top-line growth and 8% EPS growth, alongside a growing dividend [32][33] Product Development and Market Position - The surgical robot is expected to see significant growth, with positive feedback from international markets [34][36] - Medtronic is optimistic about the diabetes segment, with the 780G system showing promising results in trials [41][43] - The company is also focused on the renal denervation (RDN) market, with ongoing trials expected to yield positive results [48][49] Market Dynamics in China - Short-term challenges include navigating COVID lockdowns and pricing pressures, but long-term growth in China is still anticipated [53][54] - Medtronic acknowledges increased risks in the Chinese market due to geopolitical factors but remains bullish on investment opportunities [55] Capital Allocation and Portfolio Management - Medtronic is conducting a deep dive into its portfolio to ensure capital is allocated to higher-growth areas [57] - Ongoing evaluations may lead to divestitures or restructuring within the portfolio [57] Additional Insights - The company is adapting to a new normal in supply chain management, balancing efficiency with resiliency [11][14] - Medtronic's strategy includes leveraging acquisitions and partnerships to enhance R&D capabilities [29] - The focus on integrated insulin delivery systems positions Medtronic favorably in the diabetes market [44][46] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Medtronic's response to current challenges and its plans for future growth.

Medtronic plc (NYSE:MDT) Q4 2022 Earnings Conference Call May 26, 2022 8:00 AM ET Company Participants Ryan Weispfenning - Head of IR Geoff Martha - CEO Karen Parkhill - CFO Brad Lerman - SVP, General Counsel, Corporate Secretary Bob White - EVP and President of the Medical Surgical Portfolio Sean Salmon - EVP and President of the Cardiovascular Portfolio Conference Call Participants Vijay Kumar - Evercore ISI Travis Steed - Bank of America Merrill Lynch Larry Biegelsen - Wells Fargo Shagun Singh - RBC Ca ...

Medtronic plc (NYSE:MDT) 42nd Annual Cowen Health Care Conference Call March 7, 2022 1:30 PM ET Company Participants Karen Parkhill - Executive Vice President and Chief Financial Officer Conference Call Participants Josh Jennings - Cowen & Company Josh Jennings Good afternoon. We're continuing to move down the medical devices track at the 42nd Annual Cowen Health Care Conference. I'm Josh Jennings from the Cowen medical devices team, and we are excited to have Karen Parkhill, Executive Vice President and CF ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q ☒ QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended January 28, 2022 ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. For the transition period from __________ to __________ Commission File Number 001-36820 ® Medtronic plc (Exact name of registrant as specified in its charter) Ireland 98-1183488 (State of incorporation) (I.R ...

Medtronic plc (NYSE:MDT) Q3 2022 Earnings Conference Call February 22, 2022 8:00 AM ET Company Participants Ryan Weispfenning - Vice President and Head, Investor Relations Geoff Martha - Chairman and Chief Executive Officer Karen Parkhill - Chief Financial Officer Sean Salmon - Executive Vice President and President, Cardiovascular and Diabetes Bob White - Executive Vice President and President, Medical Surgical Brett Wall - Executive Vice President and President, Neuroscience Conference Call Participants R ...

Medtronic plc Conference Call Summary Company Overview - **Company**: Medtronic plc (NYSE: MDT) - **Event**: 40th Annual J.P. Morgan Healthcare Conference - **Date**: January 10, 2022 Key Points Industry and Company Transformation - Medtronic is undergoing a significant transformation aimed at accelerating growth and improving competitiveness, initiated 18 months ago [5][36] - The company has restructured into 20 operating units, enhancing focus and decision-making, resulting in over 70% of units now holding or winning market share, up from 35% [5][22] Financial Performance and Market Position - Medtronic has achieved over 180 product approvals in the last 12 months and continues to invest heavily in R&D and M&A [7][26] - The company expects to maintain a long-term growth profile of over 5% top-line growth and over 8% bottom-line growth [50][53] Pipeline and Product Development - Key pipeline updates include: - **Symplicity Renal Denervation**: Delays in trials but expected to tap into a multibillion-dollar market opportunity [10] - **Hugo Robotic-Assisted Surgery System**: Adjusted revenue expectations due to supply chain issues, but high customer interest remains [11] - **Diabetes Products**: Facing regulatory challenges but ongoing remediation efforts are in place [12] - The company is optimistic about its robust pipeline, which is not reliant on a few products [28] Operational Challenges and Responses - The pandemic has impacted operations, with 14 out of 20 businesses reaching pre-COVID revenue levels, but staffing shortages remain a concern [13] - The strengthening U.S. dollar is expected to create currency headwinds, estimated at $30 million to $40 million for Q3 [14][15] Quality and Safety Initiatives - Medtronic is prioritizing patient safety and quality improvements following several recalls, with a focus on enhancing operational excellence [24][48] - A new capital allocation framework is in place to better manage investments across its portfolio [25] Strategic Acquisitions - The acquisition of Affera is aimed at enhancing Medtronic's cardiac ablation portfolio, with a transaction value of nearly $1 billion [30] - The company is also focusing on strategic customer relationships to drive growth [19] ESG Commitment - Medtronic is committed to being a leader in ESG practices, focusing on innovation, patient safety, and diversity [35] Future Outlook - The company is confident in its ability to deliver double-digit total shareholder returns, driven by a strong product pipeline and market leadership across multiple segments [34][36] Additional Insights - The transformation includes cultural changes to foster a more competitive environment, with a focus on accountability and performance-based incentives [17][20] - Medtronic is leveraging technology development centers to enhance innovation and reduce costs across its business units [18] This summary encapsulates the key points discussed during the Medtronic conference call, highlighting the company's strategic direction, operational challenges, and future growth prospects.